Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus—review and meta-analysis
Tóm tắt
Diabetes increases the risk of lower extremity amputation (LEA). Although epidemiological studies report positive associations between glycaemia and LEA, the magnitude of the risk is not adequately quantified and clinical trials to date have not provided conclusive evidence about glucose lowering and LEA risk. We synthesised the available prospective epidemiological data on the association between glycaemia measured by HbA1c and the risk of LEA in individuals with diabetes. We searched electronic databases and reference lists of relevant articles. We considered prospective epidemiological studies that had measured HbA1c level and assessed LEA as an outcome among diabetic individuals without acute foot ulcerations or previous history of amputation. Of 2,548 citations identified, we included 14 studies comprising 94,640 participants and 1,227 LEA cases. We abstracted data using standardised forms and obtained data from investigators when required. Data included characteristics of study populations, HbA1c assay methods, outcome and covariates. Study-specific relative risk estimates were pooled using random-effects model meta-analysis; heterogeneity was explored with meta-regression analyses. The overall RR for LEA was 1.26 (95% CI 1.16–1.36) for each percentage point increase in HbA1c. There was considerable heterogeneity across studies (I
2 76%, 67–86%; p < 0.001), which was not accounted for by recorded study characteristics. The estimated RR was 1.44 (95% CI 1.25–1.65) for type 2 diabetes and 1.18 (95% CI 1.02–1.38) for type 1 diabetes; however, the difference was not statistically significant (p = 0.09). We found no strong evidence for publication bias. There is a substantial increase in risk of LEA associated with glycaemia in individuals with diabetes. In the absence of conclusive evidence from trials, this paper provides further epidemiological support for glucose-lowering as a strategy to reduce amputation in a population without acute foot ulceration or former amputation; it also provides disease modellers with estimates to assess the overall burden of hyperglycaemia.
Tài liệu tham khảo
Selvin E, Marinopoulos S, Berkenblit G et al (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421–431
Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
Shichiri M, Kishikawa H, Ohkubo Y, Wake N (2000) Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23(Suppl 2):B21–B29
Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
The Diabetes Control and Complications Trial Research Group (1995) Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75:894–903
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1–13
Watts SA, Daly B, Anthony M, McDonald P, Khoury A, Dahar W (2001) The effect of age, gender, risk level and glycosylated hemoglobin in predicting foot amputation in HMO patients with diabetes. J Am Acad Nurse Pract 13:230–235
Boulton AJ (1996) The pathogenesis of diabetic foot problems: an overview. Diabet Med 13(Suppl 1):S12–S16
Adler AI, Boyko EJ, Ahroni JH, Smith DG (1999) Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 22:1029–1035
Most RS, Sinnock P (1983) The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care 6:87–91
Morris AD, McAlpine R, Steinke D et al (1998) Diabetes and lower-limb amputations in the community. A retrospective cohort study. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland/Medicines Monitoring Unit. Diabetes Care 21:738–743
Schofield CJ, Libby G, Brennan GM et al (2006) Mortality and hospitalization in patients after amputation: a comparison between patients with and without diabetes. Diabetes Care 29:2252–2256
UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865
Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289
Home PD, Pocock SJ, Beck-Nielsen H et al (2007) Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 357:28–38
Moss SE, Klein R, Klein BE (1996) Long-term incidence of lower-extremity amputations in a diabetic population. Arch Fam Med 5:391–398
Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard TJ (2002) Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. Metabolism 51:248–254
Roy MS, Peng B (2008) Six-year incidence of lower extremity arterial disease and associated risk factors in type 1 diabetic African-Americans. Diabet Med 25:550–556
Coppini DV, Young PJ, Weng C, Macleod AF, Sonksen PH (1998) Outcome on diabetic foot complications in relation to clinical examination and quantitative sensory testing: a case–control study. Diabet Med 15:765–771
Lepore G, Maglio ML, Cuni C et al (2006) Poor glucose control in the year before admission as a powerful predictor of amputation in hospitalized patients with diabetic foot ulceration. Diabetes Care 29:1985
Chaturvedi N, Abbott CA, Whalley A, Widdows P, Leggetter SY, Boulton AJ (2002) Risk of diabetes-related amputation in South Asians vs Europeans in the UK. Diabet Med 19:99–104
Carrington AL, Shaw JE, van Schie CH, Abbott CA, Vileikyte L, Boulton AJ (2002) Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? Diabetes Care 25:2010–2015
Farnkvist LM, Lundman BM (2003) Outcomes of diabetes care: a population-based study. Int J Qual Health Care 15:301–307
Wells GA, Shea B, O’Connell B et al (2009) The Newcastle–Ottawa quality assessment scale. Ottawa Health Research Institute, Ottawa. Available from www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed 2 December 2009)
Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477–1482
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
Tseng CL, Sambamoorthi U, Helmer D et al (2007) The association between mental health functioning and nontraumatic lower extremity amputations in veterans with diabetes. Gen Hosp Psychiatry 29:537–546
Moss SE, Klein R, Klein BE (1999) The 14-year incidence of lower-extremity amputations in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 22:951–959
Resnick HE, Carter EA, Sosenko JM et al (2004) Incidence of lower-extremity amputation in American Indians: the Strong Heart Study. Diabetes Care 27:1885–1891
Muhlhauser I, Overmann H, Bender R, Jorgens V, Berger M (2000) Predictors of mortality and end-stage diabetic complications in patients with type 1 diabetes mellitus on intensified insulin therapy. Diabet Med 17:727–734
Lehto S, Ronnemaa T, Pyorala K, Laakso M (1996) Risk factors predicting lower extremity amputations in patients with NIDDM. Diabetes Care 19:607–612
Jbour AS, Jarrah NS, Radaideh AM et al (2003) Prevalence and predictors of diabetic foot syndrome in type 2 diabetes mellitus in Jordan. Saudi Med J 24:761–764
Davis WA, Norman PE, Bruce DG, Davis TM (2006) Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 49:2634–2641
Stettler C, Allemann S, Juni P et al (2006) Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 152:27–38
Genuth S, Nathan DM, Engel S et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653
Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139
Rajamani K, Collman PG, Best JD et al (2009) Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of randomised controlled trials. Lancet 373:1780–1788
Hunt D (2009) Diabetes: foot ulcers and amputations. Clin Evid (pii: 0602)
Schraer CD, Adler AI, Mayer AM, Halderson KR, Trimble BA (1997) Diabetes complications and mortality among Alaska Natives: 8 years of observation. Diabetes Care 20:314–321
Hennis AJ, Fraser HS, Jonnalagadda R, Fuller J, Chaturvedi N (2004) Explanations for the high risk of diabetes-related amputation in a Caribbean population of black african descent and potential for prevention. Diabetes Care 27:2636–2641
The Global Lower Extremity Amputation Study Group (2000) Epidemiology of lower extremity amputation in centres in Europe. North America and East Asia. Br J Surg 87:328–337
Krishnan S, Nash F, Baker N, Fowler D, Rayman G (2008) Reduction in diabetic amputations over 11 years in a defined U.K. population: benefits of multidisciplinary team work and continuous prospective audit. Diabetes Care 31:99–101
Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625
Boulton AJ (2008) The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev 24(Suppl 1):S3–S6
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381–389
Reiber GE, Pecoraro RE, Koepsell TD (1992) Risk factors for amputation in patients with diabetes mellitus. A case–control study. Ann Intern Med 117:97–105
Apelqvist J, Agardh CD (1992) The association between clinical risk factors and outcome of diabetic foot ulcers. Diabetes Res Clin Pract 18:43–53
Gamba MA, Gotlieb SL, Bergamaschi DP, Vianna LA (2004) Lower extremity amputations in diabetic patients: a case–control study. Rev Saude Publica 38:399–404 (Article in Portuguese)
Weinberg CR (1993) Toward a clearer definition of confounding. Am J Epidemiol 137:1–8
Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22:340–349
Pecoraro RE, Reiber GE, Burgess EM (1990) Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 13:513–521